home / stock / onct / onct short
Short Information | Oncternal Therapeutics Inc. (NYSE:ONCT)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 12,516 |
Total Actual Volume | 269,721 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 626 |
Average Short Percentage | 6.05% |
Is there a ONCT Short Squeeze or Breakout about to happen?
See the ONCT Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
02-11-2020 | $3.897 | $3.90 | $3.98 | $3.86 | 24,284 | 1,000 | 4.12% |
02-03-2020 | $3.819 | $3.75 | $3.89 | $3.72 | 23,478 | 782 | 3.33% |
01-31-2020 | $3.7694 | $3.801 | $3.918 | $3.73 | 9,234 | 46 | 0.5% |
01-30-2020 | $3.921 | $3.72 | $3.921 | $3.711 | 32,511 | 1,000 | 3.08% |
01-29-2020 | $3.8536 | $3.90 | $3.90 | $3.81 | 5,407 | 184 | 3.4% |
01-28-2020 | $3.88 | $3.9433 | $3.9433 | $3.85 | 15,368 | 1,225 | 7.97% |
01-27-2020 | $3.95 | $3.90 | $4.10 | $3.90 | 18,135 | 100 | 0.55% |
01-24-2020 | $4.00 | $3.96 | $4.1578 | $3.95 | 32,271 | 40 | 0.12% |
01-22-2020 | $4.01 | $4.12 | $4.12 | $4.01 | 10,615 | 71 | 0.67% |
01-21-2020 | $4.16 | $4.18 | $4.18 | $3.98 | 18,617 | 827 | 4.44% |
01-17-2020 | $4.12 | $4.20 | $4.20 | $4.12 | 1,697 | 221 | 13.02% |
01-16-2020 | $4.12 | $4.26 | $4.32 | $4.09 | 9,744 | 1,150 | 11.8% |
01-15-2020 | $4.2284 | $4.27 | $4.27 | $4.221 | 1,635 | 25 | 1.53% |
01-14-2020 | $4.02 | $4.15 | $4.32 | $3.95 | 29,218 | 2,560 | 8.76% |
01-13-2020 | $4.34 | $4.05 | $4.34 | $4.05 | 7,565 | 100 | 1.32% |
01-10-2020 | $4.2341 | $4.22 | $4.2607 | $4.10 | 10,623 | 60 | 0.56% |
01-09-2020 | $4.1478 | $4.26 | $4.29 | $4.1478 | 2,757 | 199 | 7.22% |
01-08-2020 | $4.1322 | $4.16 | $4.30 | $4.1313 | 4,982 | 262 | 5.26% |
01-07-2020 | $4.22 | $4.125 | $4.25 | $4.0637 | 3,645 | 664 | 18.22% |
01-06-2020 | $4.29 | $4.22 | $4.3475 | $4.18 | 7,935 | 2,000 | 25.2% |
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NYSE Market:
Fourth dosing cohort at 300 mg per day is fully enrolled for the Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors; initial data readout expected in the ...
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2024 financial results after the U.S. financial markets clo...
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the fourth cohort of its Phase 1/2 study of ONCT-5...